KR20130014523A - 라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료 - Google Patents

라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료 Download PDF

Info

Publication number
KR20130014523A
KR20130014523A KR1020127025006A KR20127025006A KR20130014523A KR 20130014523 A KR20130014523 A KR 20130014523A KR 1020127025006 A KR1020127025006 A KR 1020127025006A KR 20127025006 A KR20127025006 A KR 20127025006A KR 20130014523 A KR20130014523 A KR 20130014523A
Authority
KR
South Korea
Prior art keywords
laquinimod
subject
methotrexate
rheumatoid arthritis
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127025006A
Other languages
English (en)
Korean (ko)
Inventor
에란 블라우그룬드
노라 타식
조엘 카예
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20130014523(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20130014523A publication Critical patent/KR20130014523A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127025006A 2010-03-03 2011-03-02 라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료 Ceased KR20130014523A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33937510P 2010-03-03 2010-03-03
US61/339,375 2010-03-03
PCT/US2011/026885 WO2011109531A1 (en) 2010-03-03 2011-03-02 Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

Publications (1)

Publication Number Publication Date
KR20130014523A true KR20130014523A (ko) 2013-02-07

Family

ID=44531858

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127025006A Ceased KR20130014523A (ko) 2010-03-03 2011-03-02 라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료

Country Status (22)

Country Link
US (1) US8501766B2 (enExample)
EP (1) EP2542079B1 (enExample)
JP (1) JP5819328B2 (enExample)
KR (1) KR20130014523A (enExample)
CN (2) CN105796556A (enExample)
AU (1) AU2011223697B2 (enExample)
BR (1) BR112012022187A2 (enExample)
CA (1) CA2791709A1 (enExample)
CL (1) CL2012002424A1 (enExample)
CO (1) CO6630085A2 (enExample)
DK (1) DK2542079T3 (enExample)
EA (1) EA201290860A1 (enExample)
ES (1) ES2476368T3 (enExample)
MX (1) MX2012010066A (enExample)
NZ (1) NZ602478A (enExample)
PE (1) PE20130690A1 (enExample)
PH (1) PH12012501740A1 (enExample)
PT (1) PT2542079E (enExample)
SG (1) SG183513A1 (enExample)
SI (1) SI2542079T1 (enExample)
WO (1) WO2011109531A1 (enExample)
ZA (1) ZA201207128B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1937642E (pt) * 2005-10-19 2014-11-25 Teva Pharma Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos
NZ573846A (en) 2006-06-12 2012-01-12 Teva Pharma Stable laquinimod preparations
EP2682120B1 (en) 2007-12-20 2016-08-03 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2010028015A2 (en) * 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
US20100322900A1 (en) * 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
BR112012002124A2 (pt) * 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
DK2467372T3 (en) 2009-08-10 2016-08-22 Teva Pharma TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD
BR112012021905A2 (pt) * 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
KR20130092558A (ko) 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
US8889627B2 (en) 2011-10-12 2014-11-18 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
AU2013221304B2 (en) 2012-02-16 2017-12-21 Teva Pharmaceutical Industries Ltd. N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
AU2014236232A1 (en) 2013-03-14 2015-11-05 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
MX2015010967A (es) 2013-03-14 2015-10-26 Teva Pharma Formulaciones transdermicas de laquinimod.
JP2017514824A (ja) 2014-04-29 2017-06-08 テバ ファーマシューティカル インダストリーズ リミティド 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド
CN115281149A (zh) * 2021-05-12 2022-11-04 四川大学华西医院 一种临床前类风湿关节炎(Pre-RA)小鼠模型

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
PL199781B1 (pl) 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
PE20050232A1 (es) * 2003-06-25 2005-04-01 Elan Pharm Inc Metodo y composiciones para tratar la artritis reumatoide
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
AU2005231467A1 (en) 2004-04-01 2005-10-20 Elan Pharmaceuticals, Inc. Steroid sparing agents and methods of using same
US20090048181A1 (en) 2004-09-02 2009-02-19 Schipper Hyman M Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
DK1797109T3 (en) 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EP1933873A4 (en) 2005-10-13 2009-12-02 Human Genome Sciences Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF PATIENTS WITH POSITIVE DISEASES FOR SELF-ANTIBODIES
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
PT1937642E (pt) 2005-10-19 2014-11-25 Teva Pharma Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos
CA2623879C (en) 2005-10-26 2014-03-25 Laboratoires Serono S.A. Sulfonamide derivatives and use thereof for the modulation of metalloproteinases
US20080108641A1 (en) 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
EP2007392A4 (en) 2006-02-28 2010-04-07 Elan Pharm Inc METHOD FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH ALPHA-4-INHIBITABLE COMPOUNDS
CA3127202A1 (en) 2006-02-28 2007-09-07 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
BRPI0708392A2 (pt) 2006-03-03 2011-05-24 Elan Pharm Inc métodos de tratamento de um paciente com uma doença inflamatória ou autoimune com natalizumab e de uso de natalizumab para tratar um paciente com uma doença inflamatória ou autoimune
EP2010214A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
WO2007139887A2 (en) 2006-05-22 2007-12-06 Cargill, Incorporated Methods for treating bone or joint inflammation
US20080118553A1 (en) 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
NZ573846A (en) 2006-06-12 2012-01-12 Teva Pharma Stable laquinimod preparations
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
EP2111230A4 (en) 2006-12-19 2010-11-17 Merrimack Pharmaceuticals Inc COADMINISTRATION OF ALPHA-FOETOPROTEIN AND AN IMMUNOMODULATING AGENT FOR TREATING MULTIPLE SCLEROSIS
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
DK2187882T3 (da) 2007-07-11 2013-04-08 Medicinova Inc Behandling af progressiv neurodegenerativ sygdom med ibudilast
EP2682120B1 (en) 2007-12-20 2016-08-03 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
WO2010028015A2 (en) 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
WO2010057006A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20100322900A1 (en) 2009-06-19 2010-12-23 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with laquinimod
BR112012002124A2 (pt) 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
DK2467372T3 (en) 2009-08-10 2016-08-22 Teva Pharma TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD
BR112012021905A2 (pt) 2010-03-03 2015-09-29 Teva Pharma tratamento de nefrite lúpica usando laquinimod
KR20130036217A (ko) 2010-03-03 2013-04-11 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 관절염의 치료
JP5934202B2 (ja) 2010-07-09 2016-06-15 テバ ファーマシューティカル インダストリーズ リミティド ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用
KR20130092558A (ko) 2010-07-09 2013-08-20 테바 파마슈티컬 인더스트리즈 리미티드 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도
MX2013006464A (es) 2010-12-07 2013-07-29 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple.
EP2736335A4 (en) 2011-07-28 2015-01-07 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS USING A COMBINATION OF LAQUINIMOD AND GLATIRAMERATE ACETATE
WO2013016686A1 (en) 2011-07-28 2013-01-31 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta

Also Published As

Publication number Publication date
EA201290860A1 (ru) 2013-04-30
BR112012022187A2 (pt) 2015-09-22
DK2542079T3 (da) 2014-08-25
SI2542079T1 (sl) 2014-08-29
PE20130690A1 (es) 2013-07-07
CL2012002424A1 (es) 2012-12-21
PT2542079E (pt) 2014-07-18
US20110218203A1 (en) 2011-09-08
CN105796556A (zh) 2016-07-27
EP2542079A1 (en) 2013-01-09
SG183513A1 (en) 2012-09-27
CN102781240A (zh) 2012-11-14
US8501766B2 (en) 2013-08-06
CO6630085A2 (es) 2013-03-01
CA2791709A1 (en) 2011-09-09
AU2011223697A1 (en) 2012-10-11
JP2013521304A (ja) 2013-06-10
ES2476368T3 (es) 2014-07-14
JP5819328B2 (ja) 2015-11-24
WO2011109531A1 (en) 2011-09-09
PH12012501740A1 (en) 2012-11-12
NZ602478A (en) 2014-09-26
EP2542079A4 (en) 2013-07-24
MX2012010066A (es) 2012-10-03
AU2011223697B2 (en) 2016-07-14
ZA201207128B (en) 2014-04-30
EP2542079B1 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
AU2011223697B2 (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
CA2813555C (en) Methods for treating hyperuricemia and related diseases
CN102791130B (zh) 使用拉喹莫德治疗狼疮肾炎
JP2016196473A (ja) ラキニモドを用いるループス関節炎の治療
HK1226940A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
KR20250136946A (ko) 트라디피턴트에 의한 치료 방법
JP2021500377A (ja) 遅延放出デフェリプロン錠剤及びその使用法
JP2020523334A (ja) 過活動膀胱の治療のためのビベグロンの投薬
TW202045180A (zh) 治療纖維化之方法
KR20180054767A (ko) 원형탈모증의 치료
HK1224599A (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
HK1224599A1 (en) Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000